PetMedix now has a new home in 12,000 square feet of brand-new laboratory and office space in BioMed Realty’s latest addition to the Babraham Research Campus, south of Cambridge, UK. In spite of the current circumstances, and whilst ensuring full safety and wellbeing of all staff in keeping with government recommendations, the move was successfully completed in one day and as originally planned.
Over the last year, PetMedix has made excellent progress on the Ky9™ and Felyne™ platforms, and drug discovery is well underway. As the science advances, the team is growing and with it the need for space has increased. As the first tenants to move into the building, PetMedix now occupy a modern and well-equipped space that has been designed precisely to their specifications.
As the company scales, it will be from this site that PetMedix will continue to innovate and develop novel antibody therapeutics for the companion animal market. These are challenging times, and it is thanks to the hard work and dedication of the PetMedix team that this move has happened and that work has been able to continue.
Dr Tom Weaver, PetMedix CEO, said:
“Our team have always worked hard and produced fantastic science, but the way they have gone above and beyond here is exceptional. We are a science-led company, but it is our people that make us who we are. PetMedix has ambitious plans that remain on track, and this move will help us maintain our trajectory of strong growth.”
As part of the move, not all laboratory equipment was required at the new site. All functional laboratory equipment that was not moved has instead been donated to the NHS for use in COVID-19 research, including four laminar flow cabinets suitable for tissue culture.